[go: up one dir, main page]

WO2009011426A1 - γ-セクレターゼの新規基質c-Metを利用したスクリーニング方法 - Google Patents

γ-セクレターゼの新規基質c-Metを利用したスクリーニング方法 Download PDF

Info

Publication number
WO2009011426A1
WO2009011426A1 PCT/JP2008/063037 JP2008063037W WO2009011426A1 WO 2009011426 A1 WO2009011426 A1 WO 2009011426A1 JP 2008063037 W JP2008063037 W JP 2008063037W WO 2009011426 A1 WO2009011426 A1 WO 2009011426A1
Authority
WO
WIPO (PCT)
Prior art keywords
met
secretase
screening method
method utilizing
novel substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/063037
Other languages
English (en)
French (fr)
Inventor
Eiji Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Priority to JP2009523688A priority Critical patent/JPWO2009011426A1/ja
Priority to EP08791346A priority patent/EP2177623A4/en
Publication of WO2009011426A1 publication Critical patent/WO2009011426A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

　本発明は、γ-セクレターゼによるc-Metのプロセシングに影響を与える化合物をスクリーニングする方法であって、以下のステップ： 　　(i)候補化合物の存在下および非存在下で、γ-セクレターゼまたはその生物学的に活性な断片を含む第１の生物学的組成物と、c-Metを含む第２の生物学的組成物とを接触させ； 　　(ii)当該候補化合物の存在下および非存在下における当該c-Metの開裂をそれぞれ測定し； 　　(iii)γ-セクレターゼによる当該c-Metの開裂に影響を与える候補化合物を選択し；そして 　　(iv)前記(iii)で得られた候補化合物を、γ-セクレターゼによるc-Metのプロセシングに影響を与える化合物であると同定する、 ことを含む、上記方法。
PCT/JP2008/063037 2007-07-19 2008-07-18 γ-セクレターゼの新規基質c-Metを利用したスクリーニング方法 Ceased WO2009011426A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009523688A JPWO2009011426A1 (ja) 2007-07-19 2008-07-18 γ−セクレターゼの新規基質ｃ−Ｍｅｔを利用したスクリーニング方法
EP08791346A EP2177623A4 (en) 2007-07-19 2008-07-18 SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95062107P 2007-07-19 2007-07-19
US60/950,621 2007-07-19
US95149307P 2007-07-24 2007-07-24
US60/951,493 2007-07-24

Publications (1)

Publication Number Publication Date
WO2009011426A1 true WO2009011426A1 (ja) 2009-01-22

Family

ID=40259752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063037 Ceased WO2009011426A1 (ja) 2007-07-19 2008-07-18 γ-セクレターゼの新規基質c-Metを利用したスクリーニング方法

Country Status (4)

Country Link
US (1) US20090191580A1 (ja)
EP (1) EP2177623A4 (ja)
JP (1) JPWO2009011426A1 (ja)
WO (1) WO2009011426A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166110B1 (en) * 2007-06-08 2012-02-22 Eisai R&D Management Co., Ltd. Screening method utilizing novel substrate epha4 for gamma-secretase
JPWO2009017234A1 (ja) * 2007-08-01 2010-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ｃ−Ｒｅｔを利用したスクリーニング方法
US8530181B2 (en) * 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
DK2223999T3 (en) * 2007-11-30 2017-12-18 Eisai R&D Man Co Ltd EPHA4 POLYPEPTIDE WITH UNKNOWN ACTIVITY AND USE THEREOF
BR112013010687A2 (pt) 2010-11-03 2016-08-02 Argen X Bv combinações de anticorpos c-met
US8865426B2 (en) 2010-12-17 2014-10-21 Eisai R&D Management Co., Ltd. Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator
JP5961608B2 (ja) 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068361A1 (en) * 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
US20070026409A1 (en) * 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20060241074A1 (en) * 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
EP1478772A2 (en) * 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
JP2004000060A (ja) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
EP1947193A1 (en) * 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
EP2166110B1 (en) * 2007-06-08 2012-02-22 Eisai R&D Management Co., Ltd. Screening method utilizing novel substrate epha4 for gamma-secretase
US20090023158A1 (en) * 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase
JPWO2009017234A1 (ja) * 2007-08-01 2010-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ｃ−Ｒｅｔを利用したスクリーニング方法
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US8530181B2 (en) * 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
DK2223999T3 (en) * 2007-11-30 2017-12-18 Eisai R&D Man Co Ltd EPHA4 POLYPEPTIDE WITH UNKNOWN ACTIVITY AND USE THEREOF
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AKIMOTO M, BABA A, IKEDA-MATSUO Y, YAMADA MK, ITAMURA R, NISHIYAMA N, IKEGAYA Y, MATSUKI N.: "Hepatocyte growth factor as an enhancer of nmda currents and synaptic plasticity in the hippocampus", NEUROSCIENCE, vol. 128, no. 1, 2004, pages 155 - 62
GEORGAKOPOULOS A. ET AL.: "Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling", EMBO J., vol. 25, March 2006 (2006-03-01), pages 1242 - 1252, XP008129422 *
KOPAN R. ET AL.: "Gamma-secretase: proteasome of the membrane?", NAT. REV. MOL. CELL BIOL., vol. 5, June 2004 (2004-06-01), pages 499 - 504, XP008061885 *
LANDMAN ET AL., CYTOKINE & GROWTH FACTOR REVIEW, vol. 15, 2004, pages 337 - 351
NATH D. ET AL.: "Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase", J. CELL SCI., vol. 114, March 2001 (2001-03-01), pages 1213 - 1220, XP008129432 *
POZNER-MOULIS ET AL., CANCER RESEARCH, vol. 66, 2006, pages 7976 - 7982
SAURA CA, CHOI SY, BEGLOPOULOS V, MALKANI S, ZHANG D, SHANKARANARAYANA RAO BS, CHATTAGI S, KELLEHER RJ 3RD, KANDEL ER, DUFF K: "Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration", NEURON, vol. 42, no. 1, 8 April 2004 (2004-04-08), pages 23 - 36
See also references of EP2177623A4
TYNDALL SJ, WALIKONIS RS.: "The receptor tyrosine kinase Met and its ligand hepatocyte growth factor are clustered at excitatory synapses and can enhance clustering of synaptic proteins", CELL CYCLE, vol. 5, no. 14, 17 July 2006 (2006-07-17), pages 1560 - 8
VIDAL G.A. ET AL.: "Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities", J. BIOL. CHEM., vol. 280, no. 20, May 2005 (2005-05-01), pages 19777 - 19783, XP008129417 *

Also Published As

Publication number Publication date
US20090191580A1 (en) 2009-07-30
JPWO2009011426A1 (ja) 2010-09-24
EP2177623A4 (en) 2010-12-29
EP2177623A1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
WO2008150010A1 (ja) γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法
WO2009011426A1 (ja) γ-セクレターゼの新規基質c-Metを利用したスクリーニング方法
TWI369402B (en) Protease screening methods and proteases identified thereby
WO2006078289A3 (en) Bio-barcode based detection of target analytes
WO2007120265A3 (en) Coded molecules for detecting target analytes
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
WO2009064006A1 (ja) γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法
WO2010019414A3 (en) Detecting nucleic acid
EP1952280B8 (en) System, method&computer program product for concept based searching&analysis
WO2007098184A3 (en) Methods and compositions for analyte detection
EP2314632A3 (en) Oligosaccharidic compounds derived from heparin
WO2005003394A3 (en) Bio-barcode based detection of target analytes
WO2007045865A3 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders such as schizophrenia
WO2002054067A3 (en) Detection of analytes
WO2008082713A3 (en) Integrated semiconductor bioarray
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
WO2011144914A3 (en) Diagnostic methods
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2007079197A3 (en) Kit for taking biopsies, autopsies, excisions, and resections and methods thereof
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2007133704A3 (en) A non-nucleic acid based biobarcode assay for detection of biological materials
WO2006069023A3 (en) Assay method and apparatus with reduced sample matrix effects
WO2007035864A3 (en) Electrophoresis standards, methods and kits
WO2008020823A3 (en) Cooperative reporter systems, components, and methods for analyte detection
WO2009017234A1 (ja) γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791346

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009523688

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008791346

Country of ref document: EP